CN105943958A - 一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法 - Google Patents
一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法 Download PDFInfo
- Publication number
- CN105943958A CN105943958A CN201610385667.7A CN201610385667A CN105943958A CN 105943958 A CN105943958 A CN 105943958A CN 201610385667 A CN201610385667 A CN 201610385667A CN 105943958 A CN105943958 A CN 105943958A
- Authority
- CN
- China
- Prior art keywords
- parts
- superfine powder
- auricularia
- gout
- inonqqus obliquus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 93
- 239000007787 solid Substances 0.000 title claims abstract description 27
- 239000002245 particle Substances 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title abstract description 5
- 241000414067 Inonotus obliquus Species 0.000 title abstract description 4
- 239000002131 composite material Substances 0.000 title abstract 3
- 239000000843 powder Substances 0.000 claims abstract description 86
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 34
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 34
- 210000000582 semen Anatomy 0.000 claims abstract description 34
- 239000002994 raw material Substances 0.000 claims abstract description 28
- 241000283690 Bos taurus Species 0.000 claims abstract description 27
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 23
- 229940013618 stevioside Drugs 0.000 claims abstract description 23
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000019202 steviosides Nutrition 0.000 claims abstract description 23
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 22
- 239000000600 sorbitol Substances 0.000 claims abstract description 22
- 230000001954 sterilising effect Effects 0.000 claims abstract description 13
- 244000269722 Thea sinensis Species 0.000 claims abstract description 7
- 238000001816 cooling Methods 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 238000004806 packaging method and process Methods 0.000 claims abstract description 4
- 241000221377 Auricularia Species 0.000 claims description 38
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 33
- 241000628997 Flos Species 0.000 claims description 30
- 210000003022 colostrum Anatomy 0.000 claims description 25
- 235000021277 colostrum Nutrition 0.000 claims description 25
- 239000008187 granular material Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 15
- 238000010298 pulverizing process Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 244000227271 Cleome gynandra Species 0.000 claims description 4
- 235000012469 Cleome gynandra Nutrition 0.000 claims description 4
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 240000003553 Leptospermum scoparium Species 0.000 claims description 3
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 3
- 244000285940 beete Species 0.000 claims description 3
- 235000011222 chang cao shi Nutrition 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 241000209219 Hordeum Species 0.000 claims 9
- 240000005827 Phyllostachys nigra Species 0.000 claims 3
- 235000010717 Phyllostachys nigra Nutrition 0.000 claims 3
- 235000006468 Thea sinensis Nutrition 0.000 claims 1
- 240000005979 Hordeum vulgare Species 0.000 abstract description 25
- 208000024891 symptom Diseases 0.000 abstract description 12
- 230000036039 immunity Effects 0.000 abstract description 11
- 241000233866 Fungi Species 0.000 abstract description 10
- 241000717675 Clerodendranthus Species 0.000 abstract 1
- 240000003915 Lophatherum gracile Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 238000005453 pelletization Methods 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 43
- 239000003814 drug Substances 0.000 description 37
- 230000000694 effects Effects 0.000 description 35
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 28
- 229940116269 uric acid Drugs 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 230000036407 pain Effects 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 206010003246 arthritis Diseases 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 9
- 235000018185 Betula X alpestris Nutrition 0.000 description 8
- 235000018212 Betula X uliginosa Nutrition 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 230000029142 excretion Effects 0.000 description 8
- 239000011148 porous material Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 206010025482 malaise Diseases 0.000 description 6
- 230000002085 persistent effect Effects 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 241000213006 Angelica dahurica Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 208000012659 Joint disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 208000026816 acute arthritis Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical class [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- -1 triterpenoid compound Chemical class 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000252229 Carassius auratus Species 0.000 description 2
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- 241000199627 Rhynchonelliformea Species 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 235000021167 banquet Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001171 synovial bursa Anatomy 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-M 6,8-dioxo-6,7,8,9-tetrahydro-1H-purin-2-olate Chemical compound [N-]1C(=O)N=C2NC(=O)NC2=C1O LEHOTFFKMJEONL-UHFFFAOYSA-M 0.000 description 1
- 208000013824 Acidemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 235000007926 Craterellus fallax Nutrition 0.000 description 1
- 240000007175 Datura inoxia Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001145 finger joint Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法,由以下重量份数的原料制成,麦绿素10‑30份、桦褐孔菌5‑25份、黑木耳4‑8份、葛根0.1‑0.5份、茯苓0.1‑0.5份、淡竹叶0.1‑0.3份、薏苡仁0.1‑0.3份、猫须草5‑15份、白芷1‑10份、牛初乳0.2‑2份、黄精0.1‑0.3份、蛹虫草1‑3份、茶树花0.1‑0.3份、甜菊糖0.2‑1份、山梨糖醇30‑50份;其制备方法包括:(1)原料预处理;(2)制备黑木耳超微粉;(3)制备多种原料超微粉;(4)混合;(5)制粒;(6)灭菌;(7)冷却包装。本发明可以有效治疗痛风,改善患者痛风症状,并且可同时提高机体免疫力。
Description
技术领域
本发明涉及食药生产技术领域,特别是涉及一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法。
背景技术
痛风是常见的一种代谢障碍性的疾病,是一种由于嘌呤生物合成代谢增加,尿酸产生过多或因尿酸排泄不良而致血中尿酸升高,尿酸盐结晶沉积在关节滑膜、滑囊、软骨及其他组织中引起的反复发作性炎性疾病。它是由于单钠尿酸盐结晶或尿酸在细胞外液形成超饱和状态,使其晶体在组织中沉积而造成的一组异源性疾病。
痛风是一种因嘌呤代谢障碍,又称“高尿酸血症”,属于关节炎的一种,又称代谢性关节炎。是一种由于嘌呤生物合成代谢增加,尿酸产生过多或因尿酸排泄不良而致血中尿酸升高,尿酸盐结晶沉积在关节滑膜、滑囊、软骨及其他组织中引起的反复发作性炎性疾病。它是由于单钠尿酸盐结晶或尿酸在细胞外液形成超饱和状态,使其晶体在组织中沉积而造成的一组异源性疾病。
痛风是嘌呤代谢障碍引起的代谢性疾病,但发病有明显的异质性,除高尿酸血症外可表现为急性关节炎、痛风石、慢性关节炎、关节畸形、慢性间质性肾炎和尿酸性尿路结石。临床上分为原发性和继发性两大类,原发性痛风多由先天性嘌呤代谢异常引起,常与肥胖、糖类脂类代谢紊乱、高血压、动脉硬化和冠心病等聚集发生,继发性痛风则由某些系统性疾病或者药物引起临床特点是:高尿酸血症、急性关节炎反复发作、痛风石形成、慢性关节炎和关节畸形,以及在病程后期出现肾尿酸结石和痛风性肾实质病变。
痛风病以关节液和痛风石中可找到有双折光性的单水尿酸钠结晶为其特点。其临床特征为:高尿酸血症及尿酸盐结晶、沉积所致的特征性急性关节炎、痛风石、间质性肾炎,会让你周身局部出现红、肿、热、痛的症状,严重者见关节畸形及功能障碍,常伴尿酸性尿路结石。病因分为原发性和继发性两大类。好发于男性及绝经期的女性。
女性一般在50岁之前不会发生痛风,因为雌激素对尿酸的形成有抑制作用;但是在更年期后会增加发作比率。由于尿酸在人体血液中浓度过高,在软组织如关节膜或肌腱里形成针状结晶,导致身体免疫系统过度反应(敏感)而造成痛苦的炎症。一般发作部位为大拇趾关节,踝关节,膝关节等。
长期痛风患者有发作于手指关节,甚至耳廓含软组织部分的病例。急性痛风发作部位出现红、肿、热、剧烈疼痛,一般多在子夜发作,可使人从睡眠中惊醒。痛风初期,发作多见于下肢。
男性易患痛风:痛风病在任何年龄,都可以发生。但最常见的是40岁以上的中年男人。根据最新统计,男女发病比例是20∶1。脑力劳动者,体胖者发病率较高。痛风偏爱男性的原因是:女性体内雌激素能促进尿酸排泄,并有抑制关节炎发作的作用。男性喜饮酒、赴宴,喜食富含嘌呤、蛋白质的食物,使体内尿酸增加,排出减少。有医生统计,筵席不断者,发病者占 30%,常吃火锅者发病也多。这是因为火锅原料主要是动物内脏、虾、贝类、海鲜,再饮啤酒,自然是火上浇油了。调查证明:涮一次火锅比一顿正餐摄入嘌呤高 10倍,甚至数十倍。一瓶啤酒可使尿酸升高一倍。高血压病人患痛风可能性会增加10倍。痛风与糖尿病一样是终生疾病。
世纪80年代以来,随着经济生活水平的提高,饮食结构与生活习惯发生了改变,使得痛风与高尿酸血症的发病率呈逐年递增趋势,我国痛风发病率达0.26%~0.34%,高尿酸血症的发病率达5.78%~13.8%,痛风所伴随的高尿酸血症也已经成为冠心病、高血压的重要危险因素之一。
目前,随着社会进步的不断发展,发病率有再次升高的趋势,痛风以发病率高,治愈困难,愈后复发率高,伴有多种合并症发生,被列为著名的疑难杂症。
市场上销售的用于痛风治疗的药多为西药或痛风茶等。西药治疗痛风主要选秋水仙碱、非甾体抗炎药、激素、促进尿酸排泄药和抑制尿酸合成药为主,这些药物在治疗上疗效差、副作用大,增加肾脏负担,大多只能稳定病情,不能根治,还会引起严重的副作用造成肝肾功能的损害;即使近期治疗有效,也不能控制病情复发,而且可产生耐药性和抵抗性,甚至会出现白细胞减少、心脏功能受损、肝肾功能受损、刺激肠胃系统等合并症;而痛风茶治疗是增加尿酸排泄量,减轻尿酸盐沉积,但大量的尿酸排放会影响肾功能。
发明内容
本发明的目的是提供一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法,可以有效治疗痛风,改善患者痛风症状,具有吸收好、见效快、无毒副作用,可同时提高机体免疫力等多种优点。
本发明的目的通过以下技术方案来实现:
一种治疗痛风的桦褐孔菌复合固体颗粒,由以下重量份数的原料制成,麦绿素10-30份、桦褐孔菌5-25份、黑木耳4-8份、葛根0.1-0.5份、茯苓0.1-0.5份、淡竹叶0.1-0.3份、薏苡仁0.1-0.3份、猫须草5-15份、白芷1-10份、牛初乳0.2-2份、黄精0.1-0.3份、蛹虫草1-3份、茶树花0.1-0.3份、甜菊糖0.2-1份、山梨糖醇30-50份。
优选方案1:
一种治疗痛风的桦褐孔菌复合固体颗粒,由以下重量份数的原料制成,麦绿素30份、桦褐孔菌25份、黑木耳8份、葛根0.3份、茯苓0.3份、淡竹叶0.2份、薏苡仁0.2份、猫须草5份、白芷1份、牛初乳0.2份、黄精0.1份、蛹虫草1份、茶树花0.1份、甜菊糖0.3份、山梨糖醇30份。
优选方案2:
一种治疗痛风的桦褐孔菌复合固体颗粒,由以下重量份数的原料制成,麦绿素20份、桦褐孔菌15份、黑木耳6份、葛根0.1份、茯苓0.1份、淡竹叶0.1份、薏苡仁0.1份、猫须草15份、白芷10份、牛初乳2份、黄精0.3份、蛹虫草3份、茶树花0.3份、甜菊糖0.3份、山梨糖醇50份。
优选方案3:
一种治疗痛风的桦褐孔菌复合固体颗粒,由以下重量份数的原料制成,麦绿素10份、桦褐孔菌5份、黑木耳4份、葛根0.5份、茯苓0.5份、淡竹叶0.3份、薏苡仁0.3份、猫须草10份、白芷5份、牛初乳1.1份、黄精0.2份、蛹虫草2份、茶树花0.2份、甜菊糖0.3份、山梨糖醇40份。
最佳方案:
一种治疗痛风的桦褐孔菌复合固体颗粒,由以下重量份数的原料制成,麦绿素20份、桦褐孔菌15份、黑木耳5.6份、葛根0.3份、茯苓0.4份、淡竹叶0.3份、薏苡仁0.2份、猫须草10份、白芷5份、牛初乳1.2份、黄精0.2份、蛹虫草1份、茶树花0.2份、甜菊糖0.3份、山梨糖醇40份。
所述一种治疗痛风的桦褐孔菌复合固体颗粒,其制备方法包括以下工序,
(1)原料预处理:
按重量份数,称取优质的麦绿素、桦褐孔菌、黑木耳、葛根、茯苓、淡竹叶、薏苡仁、猫须草、白芷、牛初乳、甜菊糖、黄精、蛹虫草、茶树花、山梨糖醇,备用;其中,取桦褐孔菌、黑木耳、葛根、茯苓、淡竹叶、薏苡仁、猫须草、白芷、黄精、蛹虫草、茶树花,洗净除杂后干燥;
(2)制备黑木耳超微粉:
取洗净干燥后的黑木耳,置于超微粉碎机内超微粉碎,粉碎后过80目筛,得黑木耳超微粉;
按重量份数称取黑木耳超微粉,备用;
(3)制备多种原料超微粉:
取洗净干燥后的桦褐孔菌、葛根、茯苓、淡竹叶、薏苡仁、猫须草、白芷、黄精、蛹虫草、茶树花,分别进行烘干,烘干后分别置于超微粉碎机内进行超微粉碎,粉碎后过80目筛后;
粉碎后分别置于干燥箱内烘干至水分含量在2%以下,得到多种超微粉;按重量粉碎称取桦褐孔菌超微粉、葛根超微粉、茯苓超微粉、淡竹叶超微粉、薏苡仁超微粉、猫须草超微粉、白芷超微粉、黄精超微粉、蛹虫草超微粉、茶树花超微粉,备用;
取备用的麦绿素,置于超微粉碎机内进行超微粉碎,粉碎后过80目筛后,得麦绿素超微粉,备用;
(4)混合:
取称取后的黑木耳超微粉、桦褐孔菌超微粉、葛根超微粉、茯苓超微粉、淡竹叶超微粉、薏苡仁超微粉、猫须草超微粉、白芷超微粉、黄精超微粉、蛹虫草超微粉、茶树花超微粉,置于三维混合机中,混合均匀;加入超微粉碎后的麦绿素超微粉,并加入称取后的牛初乳,再次混合均匀;得到混合物料,备用;
(5)制粒:
取混合物料,按重量份数加入甜菊糖、山梨糖醇,混合均匀后,加入50%的乙醇,置于摇摆制粒机中制粒,得到颗粒状的混合物,取颗粒状的混合物置于烘干箱内,烘干至水分含量在3%以下,得到混合颗粒;
(6)灭菌:
取混合颗粒,置于紫外线照射灭菌机中进行紫外照射灭菌,备用;
(7)冷却包装:
取灭菌后的混合颗粒,冷却至室温后,按包装标准进行分装,即得成品。
本发明的有益效果:本发明采用麦绿素、桦褐孔菌、黑木耳为主料,葛根、茯苓、淡竹叶、薏苡仁、猫须草、白芷、牛初乳、黄精、蛹虫草、茶树花为辅料,并添加适量的甜菊糖、山梨糖醇进行加工制作,制得的桦褐孔菌复合固体颗粒可以有效治疗痛风,改善患者痛风症状,治标治本,具有吸收好、见效快、无副作用,可同时提高机体免疫力等多种优点。
本发明所采用的原料优质,通过科学配比设计出改善痛风患者症状的配方,无任何毒副作用,而本产品选用的为中药及药食兼用的原料,在治疗痛风的同时又增强免疫力,又可以提高肾脏功能,清除体内自由基,可从根本改善痛风症状。
本发明所使用的原料中,各种原料所起到的功效分别为:
(1)麦绿素的功效:
麦绿素是强碱性食品,痛风患者服用有利于体内尿酸的中和。更重要是麦绿素中SOD酶的作用,麦绿素由于采用了先进的工艺,保留的酶有100多种,其中有超氧化物歧化酶即SOD酶,能够消灭致使人体衰老的自由基,SOD酶对保护人体健康至关重要。麦绿素中的SOD酶能够帮助人体维持正常生理活动,免受自由基的侵害。自由基可破坏人体胶原蛋白和结蒂组织,干扰重要的生理过程,引起细胞DNA突变。自由基与痛风和关节炎疾病有关,关节炎就是自由基引起关节膜及关节滑液而导致的关节疾病。
(2)桦褐孔菌的功效:
含有多糖、桦褐孔菌素、桦褐孔菌醇、多种氧化三萜类化合物、栓菌酸、多种羊毛甾醇型三萜类化合物、叶酸衍生物、芳香族的香草酸、丁香酸及γ羟基苯甲酸,及木质素类化合物,能够清除体内自由基,自由基可引起关节疾病,从而起到改善关节疾病的症状。桦褐孔菌含有大量的抗癌、降血压、降血糖、复活免疫作用的植物纤维类多糖体,可以提高免疫细胞的活力,提高机体免疫力。
(3)黑木耳的功效:
黑木耳营养极为丰富,据史料记载,它是上古时代帝王独享之佳品,含有大量的碳水化合物、蛋白质、铁、钙、磷、胡萝卜素、维生素等营养物质,每100克中含钙375毫克,相当于鲫鱼的7倍;含铁185毫克,相当于鲫鱼的70倍。黑木耳还有多种药用价值,是一种珍贵的药材。黑木耳还具有滋补、润燥、养血益胃、活血止血、润肺、润肠的功效,可治疗血虚气亏、产后虚弱、降三高,还可提高免疫力。
(4)葛根的功效:
葛根的有效成分为葛根黄酮,既能有效抑制尿酸的合成,又能扩张血管,改善循环,特别是能改善肾脏的血液循环,防治尿酸结晶沉积于皮下、小血管及关节中,对于防止痛风发作有特效。
(5)茯苓的功效:
茯苓味甘、淡,性平。归心、肺、脾、肾经,具有利水渗湿、健脾、宁心的功效。可用于软化血管、辅助降低血脂、宁心安神、增强机体免疫、渗湿利尿,可减少肾脏对尿酸的吸收,调节酸碱平衡、碱化尿液、促进尿酸排泄,减轻尿酸盐沉积。
(6)淡竹叶的功效:
淡竹叶主烦热口渴、小便赤涩,可治疗牙龈肿痛,口腔炎症,具有清凉解热、利尿的作用,可增加尿酸的排出,减少尿酸结晶在体内沉积,减轻痛风症状。
(7)薏苡仁的功效:
薏苡仁性味甘淡微寒,有利水消肿、健脾去湿、舒筋除痹、清热排脓的功能,具有镇静、镇痛及解热作用,对风湿痹痛患者有良效;且其还可延缓衰老,提高机体的免疫能力。
(8)猫须草的功效:
猫须草因花像猫须而得名,又因对肾病具有特殊的疗效而取名“肾茶”,猫须草中含有黄酮、酚酸、皂苷、多酚类化合物、矿物质等200多种丰富的活性成分。清热解毒,消肿化石,能够快速修复肾独团沉积长期对肾小球和肾小管的损伤,增强肾脏过滤排泄功能,分解尿酸、结石沉积,是结石斑块逐渐缩小排出,彻底缓解痛风、风湿、肾结石、膀胱结石、尿结石及其引起的腰腿关节疼痛等症。
(9)白芷的功效:
白芷又名香白芷。性温,祛风解表、散寒止痛、除湿通窍、消肿排脓,还具有抗炎作用,改善局部血液循环,可以改善尿酸盐过多沉积引起的关节疾病,促进细胞新陈代谢。
(10)牛初乳的功效:
牛初乳是母牛产犊后3天内的乳汁,其营养成分与普通牛奶相比,含有较高蛋白质,而脂肪和糖含量则较低。牛初乳亦含有大量的免疫和生长因子,如免疫球蛋白、乳铁蛋白、溶菌酶、类胰岛素生长因子、表皮生长因子等,含珍贵的活性免疫球蛋白(IgG、IgA、IgM、IgE、IgD)及丰富的乳钙质、蛋白质、多种微量元素等营养成份。具有增强抵抗力和免疫力促进生长发育、提高智商消除疲劳、延缓衰老、增强体质、提高运动性能等多种功效。
(11)黄精的功效:
黄精可以治疗脾胃虚弱、食欲不振,痛风患者由于尿酸排泄的过多会对肾造成负担,严重尿酸盐结晶会在肾脏堆积;黄精具有较强的补肾功能,具有保健肾脏的功能。
(12)蛹虫草的功效:
蛹虫草具有抗肿瘤、抗病毒、抗菌、清除自由基、抗癌、促进机体新陈代谢的功效。可提高机体免疫力、补肾润肺、化血化痰、益气生津、加速体内尿酸等新陈代谢无的排泄。
(13)茶树花的功效:
茶树花含有丰富的蛋白质、茶多糖、茶多酚、活性抗氧化物质,茶树花内含成分具有解毒、抑菌、降糖、延缓衰老、防癌抗癌和增强免疫力的功效,增强细胞活性,抵抗自由基的侵袭。
具体实施方式
下面结合具体实施例对本发明作进一步详细说明。
实施例1
一种治疗痛风的桦褐孔菌复合固体颗粒,由以下重量份数的原料制成,麦绿素10-30份、桦褐孔菌5-25份、黑木耳4-8份、葛根0.1-0.5份、茯苓0.1-0.5份、淡竹叶0.1-0.3份、薏苡仁0.1-0.3份、猫须草5-15份、白芷1-10份、牛初乳0.2-2份、黄精0.1-0.3份、蛹虫草1-3份、茶树花0.1-0.3份、甜菊糖0.2-1份、山梨糖醇30-50份。
所述一种治疗痛风的桦褐孔菌复合固体颗粒,其制备方法包括以下工序,
(1)原料预处理:
按重量份数,称取优质的麦绿素、桦褐孔菌、黑木耳、葛根、茯苓、淡竹叶、薏苡仁、猫须草、白芷、牛初乳、甜菊糖、黄精、蛹虫草、茶树花、山梨糖醇,备用;其中,取桦褐孔菌、黑木耳、葛根、茯苓、淡竹叶、薏苡仁、猫须草、白芷、黄精、蛹虫草、茶树花,洗净除杂后干燥;
(2)制备黑木耳超微粉:
取洗净干燥后的黑木耳,置于超微粉碎机内超微粉碎,粉碎后过80目筛,得黑木耳超微粉;
按重量份数称取黑木耳超微粉,备用;
(3)制备多种原料超微粉:
取洗净干燥后的桦褐孔菌、葛根、茯苓、淡竹叶、薏苡仁、猫须草、白芷、黄精、蛹虫草、茶树花,分别进行烘干,烘干后分别置于超微粉碎机内进行超微粉碎,粉碎后过80目筛后;
粉碎后分别置于干燥箱内烘干至水分含量在2%以下,得到多种超微粉;按重量粉碎称取桦褐孔菌超微粉、葛根超微粉、茯苓超微粉、淡竹叶超微粉、薏苡仁超微粉、猫须草超微粉、白芷超微粉、黄精超微粉、蛹虫草超微粉、茶树花超微粉,备用;
取备用的麦绿素,置于超微粉碎机内进行超微粉碎,粉碎后过80目筛后,得麦绿素超微粉,备用;
(4)混合:
取称取后的黑木耳超微粉、桦褐孔菌超微粉、葛根超微粉、茯苓超微粉、淡竹叶超微粉、薏苡仁超微粉、猫须草超微粉、白芷超微粉、黄精超微粉、蛹虫草超微粉、茶树花超微粉,置于三维混合机中,混合均匀;加入超微粉碎后的麦绿素超微粉,并加入称取后的牛初乳,再次混合均匀;得到混合物料,备用;
(5)制粒:
取混合物料,按重量份数加入甜菊糖、山梨糖醇,混合均匀后,加入50%的乙醇,置于摇摆制粒机中制粒,得到颗粒状的混合物,取颗粒状的混合物置于烘干箱内,烘干至水分含量在3%以下,得到混合颗粒;
(6)灭菌:
取混合颗粒,置于紫外线照射灭菌机中进行紫外照射灭菌,备用;
(7)冷却包装:
取灭菌后的混合颗粒,冷却至室温后,按包装标准进行分装,即得成品。
实施例2
一种治疗痛风的桦褐孔菌复合固体颗粒,由以下重量份数的原料制成,麦绿素30份、桦褐孔菌25份、黑木耳8份、葛根0.3份、茯苓0.3份、淡竹叶0.2份、薏苡仁0.2份、猫须草5份、白芷1份、牛初乳0.2份、黄精0.1份、蛹虫草1份、茶树花0.1份、甜菊糖0.3份、山梨糖醇30份。
其制备方法同实施例1相同。
实施例3
一种治疗痛风的桦褐孔菌复合固体颗粒,由以下重量份数的原料制成,麦绿素20份、桦褐孔菌15份、黑木耳6份、葛根0.1份、茯苓0.1份、淡竹叶0.1份、薏苡仁0.1份、猫须草15份、白芷10份、牛初乳2份、黄精0.3份、蛹虫草3份、茶树花0.3份、甜菊糖0.3份、山梨糖醇50份。
其制备方法同实施例1相同。
实施例4
一种治疗痛风的桦褐孔菌复合固体颗粒,由以下重量份数的原料制成,麦绿素10份、桦褐孔菌5份、黑木耳4份、葛根0.5份、茯苓0.5份、淡竹叶0.3份、薏苡仁0.3份、猫须草10份、白芷5份、牛初乳1.1份、黄精0.2份、蛹虫草2份、茶树花0.2份、甜菊糖0.3份、山梨糖醇40份。
其制备方法同实施例1相同。
实施例5
一种治疗痛风的桦褐孔菌复合固体颗粒,由以下重量份数的原料制成,麦绿素20份、桦褐孔菌15份、黑木耳5.6份、葛根0.3份、茯苓0.4份、淡竹叶0.3份、薏苡仁0.2份、猫须草10份、白芷5份、牛初乳1.2份、黄精0.2份、蛹虫草1份、茶树花0.2份、甜菊糖0.3份、山梨糖醇40份。
其制备方法同实施例1相同。
实施例6
本发明临床试验:
选取患者100例,运用本发明治疗,以3个月和六个月为观察点,观察治疗前后的相关指标,考察治疗的疗效、毒副作用,探索治疗该病的新方法。
(1)患者100例入选标准:
符合诊断标准,且无剂型关节炎发作者。
中医诊断指标,主要采用国家中医药管理局发布的《中医病症诊断疗效标准》:
1、关节无明显红肿热痛,关节遇冷后疼痛明显,喜暖恶凉,局部皮肤色暗,舌质淡或暗淡,苔白或白腻,脉沉或沉滑。
、多见于中老年男子,可有痛风家族史。畅饮劳累、感风寒等诱发。
、初起可单关节发病,以第一趾关节为多,继则足踝、跟、手指和其他小关节,反复发作后,可伴有关节周围及耳廓、耳轮和趾、指骨间出现痛风结石。
、血尿酸、尿尿酸增高。X 线摄片检查可示软骨缘邻近关节有骨质有不整齐的穿凿样圆形缺陷。
(2)病例来源:
选取符合上述诊断标准的痛风缓解患者100例,其中男性78例,女性22例,平均年龄=46岁,平均身高=168.cm,平均体重=75kg。
(3)治疗药物:
一种治疗痛风的桦褐孔菌复合固体颗粒,服用方法为每日两次,每次一袋;服药期间停服其他痛风相关药物。
(4)观察指标:
A、观察治疗前后患者血尿酸、胆固醇、三酸甘油脂、饭前血糖、肌酐酸的变化。
、观察治疗3个月和6个月内痛风平均发作次数、发作关节数、发作持续时间、发作疼痛程度。
、观察中医证候疗效改善状况。
(5)评价标准:
西医评价标准:
针对患者治疗前后血尿酸水平、痛风发作次数、发作关节数量、持续时间及疼痛程度,(VAS评分)进行疗效评价。
评分标准(0分-10分):
0分:无痛;
3分以下:有轻微的疼痛,患者能忍受;
4分-6分:患者疼痛并影响睡眠,尚能忍受;
7分-10分:患者有渐强烈的疼痛,疼痛难忍。
中医评价标准:
证候疗效评价标准(参照《中药新药临床研究指导原则》);
A、临床疫愈:中医临床症状、体征明显改善,证候积分减少至少95%;
B、显效:中医临床症状、体征明显改善,证候积分减少>70%;
C、有效:中医临床症状、体征均有好转,证候积分减少>30%;
D、无效:中医临床症状、体征无明显改善甚至加重,证候积分不足30%。
(6)统计分析
所有数据均采用EXCEL2007管理,数据用SPSS13.0版统计软件进行分析。
计量资料采用t检验,计数资料采用x2检验,数据均采用x±s (均数±标准差)表示,为双侧检验,p<0.05为差异有统计学意义。
(7)观察结果:
对血尿酸的影响:
投药物前,尿酸值8.54±0.20mg/dl;
投药三个月后,尿酸值7.48±0.18mg/dl;
投药六个月后,尿酸数值6.97±0.2tng/dl。
投药三个月及六个月后,尿酸值有明显下降,与投药前比较值分别为0.0001 (三个月)与0.00001 (六个月),有统计意义。(见表1)。
表1对患者血尿酸的影响(mg/dl)
对胆固醇(Cholesterol)的影响:
投药物前,血中胆固醇值208.08士9.00 mg/dl;投药三个月后,血中胆固醇值199.92±6.96mg/dl;投药六个月后,血中胆固醇值199.03±7.44mg/dl。投药三个月及六月后,与投药前比较,p值分别为0.14 (三个月)与0.44 (六个月),前后并无统计意义。(见表二)。
表2 对胆固醇(Cholesterol)的影卩向(mg/dl)
对三酸甘油脂(Triglyceride)影响:
投药物前,血中三酸甘油脂值174.33±18.51 mg/dl;
投药三个月后血中三酸甘油脂值165.89±14.54mg/dl;
投药六个月后血中三酸甘油脂值159.89±16.95mg/dl。
投药三个月及六个月后,与投药前比较;p值分别为0.47 (三个月)与0.32 (六个月),前后并无统计意义。(见表3)。
表3对三酸甘油月旨(Triglyceride)的响(mg/dl)
对空腹血糖(Glucose AC)影响:
投药物前,饭前血糖值96.79±1.77 mg/dl;
投药三个月后,饭前血糖值95.82:t2.43mg/dl;
投药六个月后,饭前血糖值98.89±3.83mg/dl。
投药三个月及六个月后,与投药前比较,p值分别为0.61 (三个月)与0.51 (六个月),前后并无统计意义。(见表4)。
表4 对空腹血糖(Glucose AC)的影响(mg/dl)
对肌酐酸影响:
投药物前,血中肌if酸(Creatinine)值1.06土0.08 mg/dl;
投药三个月后,血中肌醉酸0.99士0.04mg/dl;
投药六个月后,血中肌酐酸值1.01 士0.05mg/dl。
投药三个月及六个月后,与投药前比较P值分别为0.23 (三个月)与0.24 (六个月),前后并无统计意义。(见表5)。
表5对肌酐酸的影响
痛风平均发作次数比较:
投药物前,痛风发作平均次数为4.1±2.1次/3个月;
投药三个月后,痛风发作平均次数0.9±0.8次/3个月;
治疗6个月后,痛风发作平均次数0.7±0.98次/3个月。
治疗后与治疗前相比,痛风发作平均次数均明显下降,差异有统计学意义(p<0.01)。
治疗6个月较治疗3个月,痛风平均发作次数有所降低,但无统计学意义。(见表6)。
表6痛风平均发作次数比较(次/3个月)
痛风发作关节数量比较:
投药物前,痛风发作关节数量为4.2±1.9个/次;
投药三个月后,痛风发作关节数量为2.1±0.7个/次;
治疗6个月后,痛风发作关节数量1.1±0.3个/次。
治疗后与治疗前相比,痛风发作关节数量均明显下降,差异有统计学意义(p><0.01 )。治疗6个月较治疗3个月,痛风发作关节数量也有明显降低,差异显着(p<0.01)。(见表7)。
表7痛风发作关节数比较(个/次)
痛风发作持续时间比较:
投药物前,痛风发作持续时间为13.2±8.9h/次;
投药三个月后,痛风发作持续时间为8.2±4.5h/次;
治疗6个月后,痛风发作持续时间为4.5±3.3个/次。治疗后与治疗前相比,痛风发作持续时间均明显缩短,差异有统计学意义(pCO.Ol)。治疗6个月较治疗3个月痛风发作持续时间也有明显降低,差异显着(p<0.01)。(见表8)。
表8痛风发作持续比较(h/次)
痛风发作疼痛程度比较:
投药物前,痛风发作疼痛程度VAS评分为9.3±5.4;
投药三个月后,痛风发作疼痛程度VAS评分降为5.2±3.1;
治疗6个月后,痛风发作疼痛程度VAS评分为2.3±1.4。
治疗后与治疗前相比,痛风发作疼痛程度VAS评分均明显减少,差异有统计学意义(p<0.01 )。治疗6个月较治疗3个月,痛风发作疼痛程度也有明显降低,差异显着(p<0.01)。(详见表9)。
表9痛风发作持续比较(h/次)
治疗后中医证候疗效评价:
用药后,患者有中医证候有明显改善,治疗3个月,总有效率为95.1%;治疗6个月,总有效率可达97%。
治疗3个月与治疗6个月相比,总有效率的差异无统计学意义(p>0.05),治疗6个月显效以上的病例为64人,而治疗3个月时只有50人,说明治疗时间延长,有助于改善中医临床证候的表现。(见表10)。
表10治疗后中医证候疗效评价
| 治疗时间 | n | 临床痊愈(%) | 显效 | 有效 | 无效 | 总有效率 |
| 3个月 | 100 | 4 | 50 | 41 | 5 | 95 |
| 6个月 | 100 | 2 | 64 | 31 | 3 | 97 |
Claims (6)
1.一种治疗痛风的桦褐孔菌复合固体颗粒,其特征在于:由以下重量份数的原料制成,麦绿素10-30份、桦褐孔菌5-25份、黑木耳4-8份、葛根0.1-0.5份、茯苓0.1-0.5份、淡竹叶0.1-0.3份、薏苡仁0.1-0.3份、猫须草5-15份、白芷1-10份、牛初乳0.2-2份、黄精0.1-0.3份、蛹虫草1-3份、茶树花0.1-0.3份、甜菊糖0.2-1份、山梨糖醇30-50份。
2.根据权利要求1所述的一种治疗痛风的桦褐孔菌复合固体颗粒,其特征在于:由以下重量份数的原料制成,麦绿素30份、桦褐孔菌25份、黑木耳8份、葛根0.3份、茯苓0.3份、淡竹叶0.2份、薏苡仁0.2份、猫须草5份、白芷1份、牛初乳0.2份、黄精0.1份、蛹虫草1份、茶树花0.1份、甜菊糖0.3份、山梨糖醇30份。
3.根据权利要求1所述的一种治疗痛风的桦褐孔菌复合固体颗粒,其特征在于:由以下重量份数的原料制成,麦绿素20份、桦褐孔菌15份、黑木耳6份、葛根0.1份、茯苓0.1份、淡竹叶0.1份、薏苡仁0.1份、猫须草15份、白芷10份、牛初乳2份、黄精0.3份、蛹虫草3份、茶树花0.3份、甜菊糖0.3份、山梨糖醇50份。
4.根据权利要求1所述的一种治疗痛风的桦褐孔菌复合固体颗粒,其特征在于:由以下重量份数的原料制成,麦绿素10份、桦褐孔菌5份、黑木耳4份、葛根0.5份、茯苓0.5份、淡竹叶0.3份、薏苡仁0.3份、猫须草10份、白芷5份、牛初乳1.1份、黄精0.2份、蛹虫草2份、茶树花0.2份、甜菊糖0.3份、山梨糖醇40份。
5.根据权利要求1所述的一种治疗痛风的桦褐孔菌复合固体颗粒,其特征在于:由以下重量份数的原料制成,麦绿素20份、桦褐孔菌15份、黑木耳5.6份、葛根0.3份、茯苓0.4份、淡竹叶0.3份、薏苡仁0.2份、猫须草10份、白芷5份、牛初乳1.2份、黄精0.2份、蛹虫草1份、茶树花0.2份、甜菊糖0.3份、山梨糖醇40份。
6.根据权利要求1-5任意一项所述的一种治疗痛风的桦褐孔菌复合固体颗粒,其特征在于:其制备方法包括以下工序,
(1)原料预处理:
按重量份数,称取优质的麦绿素、桦褐孔菌、黑木耳、葛根、茯苓、淡竹叶、薏苡仁、猫须草、白芷、牛初乳、甜菊糖、黄精、蛹虫草、茶树花、山梨糖醇,备用;其中,取桦褐孔菌、黑木耳、葛根、茯苓、淡竹叶、薏苡仁、猫须草、白芷、黄精、蛹虫草、茶树花,洗净除杂后干燥;
(2)制备黑木耳超微粉:
取洗净干燥后的黑木耳,置于超微粉碎机内超微粉碎,粉碎后过80目筛,得黑木耳超微粉;
按重量份数称取黑木耳超微粉,备用;
(3)制备多种原料超微粉:
取洗净干燥后的桦褐孔菌、葛根、茯苓、淡竹叶、薏苡仁、猫须草、白芷、黄精、蛹虫草、茶树花,分别进行烘干,烘干后分别置于超微粉碎机内进行超微粉碎,粉碎后过80目筛后;
粉碎后分别置于干燥箱内烘干至水分含量在2%以下,得到多种超微粉;按重量粉碎称取桦褐孔菌超微粉、葛根超微粉、茯苓超微粉、淡竹叶超微粉、薏苡仁超微粉、猫须草超微粉、白芷超微粉、黄精超微粉、蛹虫草超微粉、茶树花超微粉,备用;
取备用的麦绿素,置于超微粉碎机内进行超微粉碎,粉碎后过80目筛后,得麦绿素超微粉,备用;
(4)混合:
取称取后的黑木耳超微粉、桦褐孔菌超微粉、葛根超微粉、茯苓超微粉、淡竹叶超微粉、薏苡仁超微粉、猫须草超微粉、白芷超微粉、黄精超微粉、蛹虫草超微粉、茶树花超微粉,置于三维混合机中,混合均匀;加入超微粉碎后的麦绿素超微粉,并加入称取后的牛初乳,再次混合均匀;得到混合物料,备用;
(5)制粒:
取混合物料,按重量份数加入甜菊糖、山梨糖醇,混合均匀后,加入50%的乙醇,置于摇摆制粒机中制粒,得到颗粒状的混合物,取颗粒状的混合物置于烘干箱内,烘干至水分含量在3%以下,得到混合颗粒;
(6)灭菌:
取混合颗粒,置于紫外线照射灭菌机中进行紫外照射灭菌,备用;
(7)冷却包装:
取灭菌后的混合颗粒,冷却至室温后,按包装标准进行分装,即得成品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610385667.7A CN105943958A (zh) | 2016-06-03 | 2016-06-03 | 一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610385667.7A CN105943958A (zh) | 2016-06-03 | 2016-06-03 | 一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105943958A true CN105943958A (zh) | 2016-09-21 |
Family
ID=56907643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610385667.7A Pending CN105943958A (zh) | 2016-06-03 | 2016-06-03 | 一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105943958A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107996652A (zh) * | 2017-12-27 | 2018-05-08 | 吉林农业大学 | 一种降酸抗痛风健康饼干及其生产方法 |
| CN109329671A (zh) * | 2018-11-15 | 2019-02-15 | 杨齐辉 | 一种用于治疗痛风的食用饮制品及其制备方法 |
| CN110151982A (zh) * | 2019-05-22 | 2019-08-23 | 王树理 | 一种治疗痛风的中药组合物 |
| CN111529597A (zh) * | 2020-05-29 | 2020-08-14 | 广东众益康生物科技有限公司 | 一种用于痛风和/或高尿酸血症的中药组合物 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732623A (zh) * | 2009-12-08 | 2010-06-16 | 毕哲全 | 治疗急性痛风性关节炎的药物及其制备方法 |
| CN102754827A (zh) * | 2012-06-24 | 2012-10-31 | 宁波市鄞州浩斯瑞普生物科技有限公司 | 一种用于高尿酸血症的食品 |
| CN103518915A (zh) * | 2013-10-23 | 2014-01-22 | 桂林丰润莱生物科技有限公司 | 适宜高尿酸人群的保健茶及其制备方法 |
| CN104012729A (zh) * | 2014-06-11 | 2014-09-03 | 杨平 | 一种降尿酸袋泡代用茶 |
| CN104473977A (zh) * | 2014-11-18 | 2015-04-01 | 广东省微生物研究所 | 一种蛹虫草水提物、制备方法及其应用 |
| CN104758920A (zh) * | 2015-04-29 | 2015-07-08 | 唐凯 | 一种基于药食同源的痛风保健品 |
| CN105250817A (zh) * | 2015-11-11 | 2016-01-20 | 广东明荃生物科技有限公司 | 一种治疗痛风、关节肿痛、降尿酸的含草本植物的茶 |
-
2016
- 2016-06-03 CN CN201610385667.7A patent/CN105943958A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732623A (zh) * | 2009-12-08 | 2010-06-16 | 毕哲全 | 治疗急性痛风性关节炎的药物及其制备方法 |
| CN102754827A (zh) * | 2012-06-24 | 2012-10-31 | 宁波市鄞州浩斯瑞普生物科技有限公司 | 一种用于高尿酸血症的食品 |
| CN103518915A (zh) * | 2013-10-23 | 2014-01-22 | 桂林丰润莱生物科技有限公司 | 适宜高尿酸人群的保健茶及其制备方法 |
| CN104012729A (zh) * | 2014-06-11 | 2014-09-03 | 杨平 | 一种降尿酸袋泡代用茶 |
| CN104473977A (zh) * | 2014-11-18 | 2015-04-01 | 广东省微生物研究所 | 一种蛹虫草水提物、制备方法及其应用 |
| CN104758920A (zh) * | 2015-04-29 | 2015-07-08 | 唐凯 | 一种基于药食同源的痛风保健品 |
| CN105250817A (zh) * | 2015-11-11 | 2016-01-20 | 广东明荃生物科技有限公司 | 一种治疗痛风、关节肿痛、降尿酸的含草本植物的茶 |
Non-Patent Citations (2)
| Title |
|---|
| 张泽生等: "桦褐孔菌提取物对高尿酸血症大鼠影响的研究", 《食品科技》 * |
| 陈贵堂等: "麦绿素对生长期大鼠营养生理功能的影响", 《食品工业科技》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107996652A (zh) * | 2017-12-27 | 2018-05-08 | 吉林农业大学 | 一种降酸抗痛风健康饼干及其生产方法 |
| CN109329671A (zh) * | 2018-11-15 | 2019-02-15 | 杨齐辉 | 一种用于治疗痛风的食用饮制品及其制备方法 |
| CN110151982A (zh) * | 2019-05-22 | 2019-08-23 | 王树理 | 一种治疗痛风的中药组合物 |
| CN111529597A (zh) * | 2020-05-29 | 2020-08-14 | 广东众益康生物科技有限公司 | 一种用于痛风和/或高尿酸血症的中药组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104366636B (zh) | 一种平卧菊三七复合制剂及制备方法及应用 | |
| CN102919836B (zh) | 一种降糖、降压、降脂、通便养颜、减肥、抗疲劳保健品及其生产工艺 | |
| CN109123643A (zh) | 一种谷物代餐球的制备方法 | |
| CN103263012B (zh) | 一种药食同源的保健食品及其制备方法 | |
| CN105495258A (zh) | 一种有助降尿酸的水果饮料 | |
| CN105943958A (zh) | 一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法 | |
| CN109123351A (zh) | 一种具有高血糖人群代餐调节功能的特医食品及制备方法 | |
| CN106387900A (zh) | 一种调节血脂、血压及血糖的组合物及其应用 | |
| CN105125946A (zh) | 一种清心除烦的栀子口服液及其制备方法 | |
| CN108498568A (zh) | 用羊胎盘或胚胎治疗自体免疫性与免疫相关性疾病的中成药、医用食品及制备方法 | |
| CN104544084B (zh) | 一种用于糖尿病患者的保健食品 | |
| CN103520302A (zh) | 一种沙棘叶抗疲劳胶囊及其制备方法 | |
| CN103977390B (zh) | 一种生姜洋葱药酒组合物的制备方法及其用途 | |
| CN103920140B (zh) | 一种人用降糖减肥降脂复方制剂 | |
| CN102793870B (zh) | 一种治疗肾结石的中草药 | |
| CN111418682A (zh) | 一种提升人体免疫功能的sod聚能香袋泡茶及其制备方法 | |
| KR101391647B1 (ko) | 항비만 조성물 | |
| CN103212030B (zh) | 一种治疗肝郁型乳腺增生的中药及制备方法 | |
| CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
| CN103933282B (zh) | 一种治疗糖尿病的中药胶囊 | |
| CN101249236B (zh) | 一种治疗癫痫的中西医药结合制剂 | |
| CN105641383A (zh) | 具有减肥作用的中药含片及其制备方法 | |
| CN105995980A (zh) | 一种具有体重管理作用的组合物及其制备方法 | |
| CN101164595A (zh) | 一种治疗厌食症的中药 | |
| CN105641387A (zh) | 一种具有减肥作用的中药分散片 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Xue Inventor after: Xiao Jing Inventor after: Liu Guojun Inventor before: Xiao Jing |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |